An Evaluation of the Pharmacokinetics and Safety of Fixed and Escalating Doses of Oral Treprostinil Diethanolamine (UT-15C) Sustained Release Tablets in Patients With Systemic Sclerosis

Trial Profile

An Evaluation of the Pharmacokinetics and Safety of Fixed and Escalating Doses of Oral Treprostinil Diethanolamine (UT-15C) Sustained Release Tablets in Patients With Systemic Sclerosis

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jun 2014

At a glance

  • Drugs Treprostinil (Primary)
  • Indications Systemic scleroderma
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept
  • Acronyms DISTOL-PK
  • Sponsors United Therapeutics Corporation
  • Most Recent Events

    • 25 Jun 2014 New trial record
    • 13 Jan 2011
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top